CHEK:NSD-Check-Cap Ltd (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.15

Change

-0.23 (-16.67)%

Market Cap

USD 0.06B

Volume

5.91M

Average Target Price

USD 1.50 (+30.43%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. The company was founded in 2004 and is based in Isfiya, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

-16.80 (-4.03%)

USD60.75B 93.58 57.27
IDXX IDEXX Laboratories, Inc

-12.17 (-2.44%)

USD42.54B 74.22 54.56
DXCM DexCom, Inc

-12.43 (-3.37%)

USD35.46B 72.87 99.23
EXAS Exact Sciences Corporation

-5.55 (-4.38%)

USD21.40B N/A N/A
GH Guardant Health, Inc

-10.55 (-7.34%)

USD14.43B N/A N/A
OZON Ozon Holdings PLC

-3.83 (-6.36%)

USD12.27B N/A N/A
NTRA Natera, Inc

-6.55 (-6.03%)

USD9.41B N/A N/A
PRAH PRA Health Sciences, Inc

-1.93 (-1.33%)

USD9.27B 47.25 24.16
ICLR ICON Public Limited Company

-2.95 (-1.69%)

USD9.24B 28.45 19.18
SYNH Syneos Health, Inc

-2.15 (-2.91%)

USD7.70B 40.34 21.29

ETFs Containing CHEK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 150.00% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.00% 98% A+ 98% A+
Trailing 12 Months  
Capital Gain -24.34% 9% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.34% 9% F 8% F
Trailing 5 Years  
Capital Gain -96.98% 10% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.98% 10% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -51.81% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.81% 3% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 32.32% 77% C+ 46% F
Risk Adjusted Return -160.30% 2% F N/A N/A
Market Capitalization 0.06B 9% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.20 89% B+ 91% A-
Price/Book Ratio 4.24 75% C 42% F
Price / Cash Flow Ratio -4.97 52% F 65% D
EV/EBITDA 0.23 88% B+ 94% A
Management Effectiveness  
Return on Equity -91.32% 22% F 13% F
Return on Invested Capital -146.07% 14% F 6% F
Return on Assets -47.97% 16% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.32 84% B 80% B-
Short Percent 7.47% 26% F 26% F
Beta 0.14 95% A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector